Journal of Surgical Oncology (J SURG ONCOL)

Publisher: Wiley InterScience (Online service), Wiley

Journal description

The Journal of Surgical Oncology published in 12 issues a year offers peer-reviewed original papers in the field of surgical oncology and broadly related surgical sciences including reports on experimental and laboratory studies related to surgical oncology. In addition peer-reviewed columns include Rapid Communications in-depth Reviews on topics of current interest and brief reports about technical innovations ("How I Do It"). Invited Editorials and Letters to the Editor round out the scope of the journal.

Current impact factor: 3.24

Impact Factor Rankings

2016 Impact Factor Available summer 2017
2014 / 2015 Impact Factor 3.244
2013 Impact Factor 2.843
2012 Impact Factor 2.644
2011 Impact Factor 2.1
2010 Impact Factor 2.428
2009 Impact Factor 2.502
2008 Impact Factor 2.478
2007 Impact Factor 2.384
2006 Impact Factor 2.183
2005 Impact Factor 1.779
2004 Impact Factor 1.758
2003 Impact Factor 1.991
2002 Impact Factor 1.502
2001 Impact Factor 1.318
2000 Impact Factor 1.541
1999 Impact Factor 1.451
1998 Impact Factor 1.023
1997 Impact Factor 0.774
1996 Impact Factor 0.634
1995 Impact Factor 0.56
1994 Impact Factor 0.443
1993 Impact Factor 0.45
1992 Impact Factor 0.499

Impact factor over time

Impact factor

Additional details

5-year impact 3.09
Cited half-life 6.10
Immediacy index 0.52
Eigenfactor 0.02
Article influence 0.90
Website Journal of Surgical Oncology website
Other titles Journal of surgical oncology (Online), Journal of surgical oncology
ISSN 0022-4790
OCLC 37988911
Material type Document, Periodical, Internet resource
Document type Internet Resource, Computer File, Journal / Magazine / Newspaper

Publisher details


  • Pre-print
    • Author can archive a pre-print version
  • Post-print
    • Author cannot archive a post-print version
  • Restrictions
    • 12 months embargo
  • Conditions
    • Some journals have separate policies, please check with each journal directly
    • On author's personal website, institutional repositories, arXiv, AgEcon, PhilPapers, PubMed Central, RePEc or Social Science Research Network
    • Author's pre-print may not be updated with Publisher's Version/PDF
    • Author's pre-print must acknowledge acceptance for publication
    • Non-Commercial
    • Publisher's version/PDF cannot be used
    • Publisher source must be acknowledged with citation
    • Must link to publisher version with set statement (see policy)
    • If OnlineOpen is available, BBSRC, EPSRC, MRC, NERC and STFC authors, may self-archive after 12 months
    • If OnlineOpen is available, AHRC and ESRC authors, may self-archive after 24 months
    • Publisher last contacted on 07/08/2014
    • This policy is an exception to the default policies of 'Wiley'
  • Classification

Publications in this journal

  • No preview · Article · Oct 2015 · Journal of Surgical Oncology

  • No preview · Article · Jun 2015 · Journal of Surgical Oncology
  • [Show abstract] [Hide abstract]
    ABSTRACT: Unroofing hepatectomy, an alternative approach to remove a deep-seated hepatocellular carcinoma (HCC) adjacent to major intrahepatic vessels by peel-off technique after sacrificing the overlying noncancerous liver, may result in tumor exposure without resection margin. The aim of the study was to examine the value of this approach in cirrhotic patients. Between 1998 and 2012, 51 cirrhotic patients underwent unroofing hepatectomy for deep-seated newly-diagnosed HCC adjacent to major intrahepatic vessels (group A). Another 274 cirrhotic patients with similar tumor size and without gross major vessel involvement in the same period were selected as the control cohort (group B). The patients' clinicopathological characteristics, the early and long-term outcomes of the two groups were compared. The HCCs in group A had a significantly higher rate of tumor encapsulation, smaller number of associated satellite nodules, and smaller amount of resected liver weight. Postoperative complication and 90-day mortality rates were similar, but group A patients had a significant better 5-year disease-free (56% vs. 32%, P = 0.011) and overall survival rates (82% vs. 53%, P = 0.008). In selected cirrhotic patients, unroofing hepatectomy facilitates resection of deep-seated HCC adjacent to major intrahepatic vessels with acceptable early and long-term results. J. Surg. Oncol. 2015 111:396-403. © 2015 Wiley Periodicals, Inc. © 2015 Wiley Periodicals, Inc.
    No preview · Article · Apr 2015 · Journal of Surgical Oncology
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background Evidence regarding the prognostic value of perineural invasion (PNI) in oral squamous cell carcinoma (OSCC) and whether PNI alone warrants consideration of adjuvant therapy is controversial. We evaluated whether histopathological sub-categorization of PNI improves risk stratification.MethodsPNI was evaluated for nerve size, number of foci, and distance from the tumor in 318 OSCC patients. Univariable and multivariable analyses were performed, with local failure (LF) and disease-specific survival (DSS) as the primary endpoints.ResultsPNI did not influence prognosis when classified as absent versus present. In contrast, multifocal PNI was associated with LF (P = 0.049) and decreased DSS (P = 0.043) on multivariable analyses. The size of the involved nerve separated those with multifocal PNI into intermediate (<1 mm) and high-risk (≥1 mm) groups. Unifocal PNI and distance from the tumor did not influence prognosis. Multifocal PNI was associated with worse prognosis irrespective of post-operative radiotherapy (PORT).Conclusions Multifocal PNI is associated with poor outcomes even with PORT suggesting consideration of therapeutic escalation, particularly with involved nerves ≥1 mm. Unifocal PNI did not affect prognosis even in the absence of PORT, which may not be required if this is the sole risk factor. Prospective validation and testing of these hypotheses is essential before implementation. J. Surg. Oncol. 2015 111:352–358. © 2014 Wiley Periodicals, Inc.
    No preview · Article · Mar 2015 · Journal of Surgical Oncology
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cyclin D1 is an important regulator protein for the G1-S cell cycle phase transition. The aim of this trial was to evaluate the impact of the CCND1 polymorphism G870A and corresponding protein expression and CCND1 amplification on the survival of the patients. 425 patients with ductal pancreatic adenocarcinoma who underwent resection were included after histopathological confirmation. DNA was analyzed for Cyclin D1 polymorphisms, immunhistochemical examination and fluorescence in situ hybridization analysis of the tumor were performed. Overall, the mean survival was 22.9 months (20.5-25.3). The survival in patients with Cyclin D1 G870A polymorphism Adenine/Adenine was 15.1 months (95% CI 11.3-18.9), 21.5 months (17.4-25.6) for Adenine/Guanine, and 29.4 months (95% CI 23.8-35.0) for Guanine/Guanine (P = 0.003). A shorter survival was associated with strong/moderate protein expression in immunohistochemistry (IHC) compared to weak/no expression (P = 0.028). Additionally, a significant coherency between unfavourable polymorphism (AA/AG) and increased protein expression was detected (P = 0.005). A strong impact on survival of Cyclin D1 G870A polymorphism and the detected corresponding protein expression was found. The biological mechanism of CCND1 in carcinogenesis has not been fully examined; but at present Cyclin D1 seems to be an interesting biomarker for the prognosis of ductal adenocarcinoma. J. Surg. Oncol. © 2014 Wiley Periodicals, Inc. © 2014 Wiley Periodicals, Inc.
    No preview · Article · Mar 2015 · Journal of Surgical Oncology
  • [Show abstract] [Hide abstract]
    ABSTRACT: Tumor mitotic rate (TMR) is an important prognostic variable for patients with thin melanoma. However it remains unclear what the significance of TMR is for more deeply invasive melanoma pathologically staged with a sentinel lymph node biopsy. We sought to determine the prognostic value of TMR in clinically node-negative T2 melanoma patients staged with sentinel lymphadenectomy. A prospective IRB-approved database of cutaneous melanoma patients treated from 09/01/1997-03/01/2011 was used to identify patients with T2 melanoma staged with a SLN. Associations were evaluated using Fisher's Exact test, and Kaplan-Meier analysis. Three hundred thirteen T2 patients were included. 19% had ulceration, 11% a positive sentinel node (SLN), and 10% recurred. 44% of patients had TMR ≥1/mm(2) . TMR ≥1/mm(2) did not predict SLN status. TMR ≥1/mm(2) was significantly associated with recurrence in SLN negative patients; only 3% of those with TMR <1/mm(2) developed a recurrence compared to 16% of those with TMR ≥1/mm(2) (P < 0.0001). Although TMR ≥1/mm(2) is not associated with risk of SLN involvement in T2 melanoma, it is a significant risk factor for recurrence when SLN negative. As such, TMR could be used to stratify follow-up regimens in SLN negative T2 patients. J. Surg. Oncol. © 2015 Wiley Periodicals, Inc. © 2015 Wiley Periodicals, Inc.
    No preview · Article · Feb 2015 · Journal of Surgical Oncology
  • [Show abstract] [Hide abstract]
    ABSTRACT: Lymph node yield (LNY) and lymph node ratio (LNR) are recognized as independent prognostic factors in colorectal cancer (CRC). To examine the relationship between LNY and other clinico-pathological variables, and the prognostic value of LNY and LNR on patient survival in CRC. The clinico-pathological and survival data for patients diagnosed from January 2000 to July 2012 were retrieved from the New Zealand Cancer Registry. Multiple linear regression was used to identify clinico-pathological factors influencing LNY, and Cox regression was used to determine the association between LNY and LNR and patient survival. 14,646 patients were included in the study (mean age 70.3 years, 50.1% male). Mean LNY was 17.4. Younger age, right-sided disease, higher T stage, female sex and no neoadjuvant radiotherapy (rectal cancer) were all associated with higher LNY (P ≤ 0.001). Overall survival in Stage I-III disease increased with higher LNY (for LNY ≥ 12, HR = 0.67, 95% CI 0.64-0.72; P < 0.001). Survival in Stage III-IV disease was inversely related to LNR (HR = 0.56, 95% CI 0.51-0.62; P < 0.001). LNY is influenced by patient age, site of disease and T stage. LNY (Stage I-II) and LNR (Stage III-IV) have independent prognostic value in CRC. J. Surg. Oncol. © 2015 Wiley Periodicals, Inc. © 2015 Wiley Periodicals, Inc.
    No preview · Article · Feb 2015 · Journal of Surgical Oncology
  • [Show abstract] [Hide abstract]
    ABSTRACT: There is overlap in the clinical presentation of benign soft tissue tumors and soft tissue sarcomas. A preoperative sarcoma diagnosis would allow for consideration for neoadjuvant therapy, including preoperative radiation, as well as optimal surgical treatment planning, and patient counseling. Image guided core needle biopsy is a low morbidity, cost-effective, highly accurate approach for obtaining a definitive pathologic diagnosis. Any biopsy approach should minimize the potential for tumor seeding of otherwise uninvolved anatomic structures. J. Surg. Oncol. © 2015 Wiley Periodicals, Inc. © 2015 Wiley Periodicals, Inc.
    No preview · Article · Feb 2015 · Journal of Surgical Oncology
  • [Show abstract] [Hide abstract]
    ABSTRACT: Although relatively rare, soft tissue sarcomas cause significant morbidity and mortality due to their advanced stage at initial diagnosis. Rehabilitation and surgical outcomes have traditionally focused on physical parameters to assess function and recovery, emphasizing return to ambulation, activities of daily living (ADLs) and community re-integration. Assessments of functional impairment and other quality-of-life parameters are necessary to better understand the experience of the patient with extremity soft tissue sarcoma and thereby improve outcomes. J. Surg. Oncol. © 2014 Wiley Periodicals, Inc. © 2014 Wiley Periodicals, Inc.
    No preview · Article · Nov 2014 · Journal of Surgical Oncology
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objectives: To identify the prognostic implications of human papillomavirus (HPV)-related cell cycle marker profiles in patients who have received a transoral lateral oropharyngectomy (TLO) as a primary treatment for tonsillar squamous cell carcinoma (TSCC). Patients and methods: Immunohistochemical profiles of HPV-related cell cycle markers, including p16, pRb, cyclin D1, p53, and the HPV DNA status of 42 consecutive TSCC patients who underwent TLO-based treatments were analyzed. The prognostic value of each marker was evaluated. Results: Univariate analysis indicated that high p16, low pRb, and low p53 expression levels are significantly associated with a good disease-free and overall survival outcome. Clinicopathological parameters and the HPV DNA status did not show prognostic significance. When adjusted for age, overall stage and treatment strategy, a high p16 and low pRb level remained an effective prognostic marker for good survival outcomes. A high p16/low pRb combination showed superior survival prediction ability over high p16 or low pRb alone. Conclusion: HPV-related cell cycle markers may also be good indicators for predicting survival after TLO for TSCC. The de-escalation TLO surgery approach would be more effective if performed under the stringent guidance of these markers.
    No preview · Article · Sep 2014 · Journal of Surgical Oncology